BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 15380067)

  • 1. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
    Shah OJ; Wang Z; Hunter T
    Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
    Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
    Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
    Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
    Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis.
    Shah OJ; Hunter T
    Mol Cell Biol; 2006 Sep; 26(17):6425-34. PubMed ID: 16914728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
    Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH
    Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
    Kwiatkowski DJ
    Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.
    Li Y; Inoki K; Guan KL
    Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
    Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
    J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.
    Inoki K; Li Y; Xu T; Guan KL
    Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
    Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
    J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
    Nobukini T; Thomas G
    Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
    Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
    Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase.
    Copps KD; Hançer NJ; Qiu W; White MF
    J Biol Chem; 2016 Apr; 291(16):8602-17. PubMed ID: 26846849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheb fills a GAP between TSC and TOR.
    Manning BD; Cantley LC
    Trends Biochem Sci; 2003 Nov; 28(11):573-6. PubMed ID: 14607085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
    Castro AF; Rebhun JF; Clark GJ; Quilliam LA
    J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
    Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP
    J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
    Harrington LS; Findlay GM; Gray A; Tolkacheva T; Wigfield S; Rebholz H; Barnett J; Leslie NR; Cheng S; Shepherd PR; Gout I; Downes CP; Lamb RF
    J Cell Biol; 2004 Jul; 166(2):213-23. PubMed ID: 15249583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheb binds and regulates the mTOR kinase.
    Long X; Lin Y; Ortiz-Vega S; Yonezawa K; Avruch J
    Curr Biol; 2005 Apr; 15(8):702-13. PubMed ID: 15854902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.